Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ARAID Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- Earnings Call ExcerptARIAD Pharmaceuticals, Inc. ARIA Q3 2008 Earnings Call Transcript November 6, 2008 8:30 a.m. ET Executives Maria E. Cantor – Vice President, Corporate Communications and Investor Relations Harvey J. Berger – Chairman and Chief Executive Officer Edward M. Fitzgerald – Senior Vice President, Chief Financial Officer...
- Earnings calls 2008-11-06
Additional Resources
- ARIAD To Pursue Phase 3 Trial Following FDA Feedback.
- M2 PRESSWIRE-6 April 2007-Businessnetwire.us: ARIAD To Pursue Phase 3 Trial Following FDA FeedbackC1994-2007 M2 COMMUNICATIONS LTD RDATE:06042007 New York, NY - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA); HealthSonix Inc. (OTC: HSXI) Business NetWire is an affiliate of Stock Profiler.US. To...
- Research articles 2007-04-06
- ARIAD Chief Executive to Appear On CNBC's "Squawk Box" on March 3, 2000 at Approximately 9:00 AM EST
- Business Editors CAMBRIDGE, Mass.--BUSINESS WIRE--March 2, 2000 ARIAD Pharmaceuticals, Inc. (Nasdaq: "ARIA") today announced that Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, is scheduled to appear on CNBC's "Squawk Box" on Friday, March 3, 2000 at approximately 9:00 am EST. He will be interviewed...
- Research articles 2000-03-02
- Don't Bury Ariad's Patent Yet
- Derek Lowe submits: Ariad's ARIA trek through the legal system has not yet ended! This story has been running for years now - I think the original lawsuit was filed in 2002. Back in the spring, a decision by the Court of Appeals for the Federal Circuit reversed a...
- External links 2009-08-27
- ARIAD Pharmaceuticals Inc.(Brief Article)
- ARIAD Pharmaceuticals Inc. has entered into a definitive agreement with Acqua Wellington North American Equities Fund for an equity financing facility covering ... ARIAD Pharmaceuticals Inc. has entered into a definitive agreement with Acqua Wellington North American Equities Fund for an equity financing...
- Research articles 2000-07-03
- ARIAD Honored by Sarcoma Foundation of America for Development of AP23573 as Breakthrough Treatment for Sarcomas
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the Company has been honored by the Sarcoma Foundation of America SFA with the Symbol of Caring Award for the discovery and development of AP23573 - ARIAD's breakthrough medicine for the treatment of soft-tissue and bone sarcomas. With over...
- Research articles 2005-06-07
- Ariad to Open NASDAQ Stock Market on February 13, 2008
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, will open the NASDAQ stock market on Wednesday, February 13, 2008. Members of the ARIAD executive leadership team and Board of Directors and distinguished guests will join Dr....
- Research articles 2008-02-11
- ARIAD Announces Public Offering of Common Stock
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced today that it proposes to offer 3,112,945 shares of its common stock pursuant to its effective shelf registration statements. The underwriter will be granted an option to purchase up to an additional 466,942 shares of ARIAD's common stock to cover over-allotments....
- Research articles 2006-10-19
- Preclinical Data on ARIAD's Molecularly Targeted Oncology Programs to Be Presented at the American Association for Cancer Research Meeting
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that investigators from leading academic cancer-research centers and ARIAD will present data from six collaborative studies focused on compounds from ARIAD's oncogenic kinase inhibitor and bone-targeted mTOR inhibitor programs at the annual meeting of the American Association for Cancer Research...
- Research articles 2006-03-28
- ARIAD Names Vice President, Clinical Operations to Further Enhance Global Clinical Development Efforts
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Ross D. Pettit, to the newly created position of vice president, clinical operations. In this role, Mr. Pettit will be responsible for overseeing the planning and implementation of a wide range of operational activities for ARIAD's clinical...
- Research articles 2007-10-02
- ARIAD Further Strengthens Medical Oncology Leadership
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced the appointment of Daniel R. Vlock, M.D. to the newly created position of vice president, clinical research. In this role, Dr. Vlock will work closely with ARIAD's chief medical officer in the leadership of the clinical development of the Company's...
- Research articles 2006-03-30
- ARIAD Announces $14 Million Financing
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced today that it has agreed to sell 3,112,945 shares of its common stock pursuant to its effective shelf registration statements in an underwritten offering. The underwriter has been granted an option to purchase up to an additional 466,942 shares of ARIAD's...
- Research articles 2006-10-20
- New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced publication, for the first time, of the high-resolution structure of the protein responsible for one of the major clinically relevant genetic variants of drug-resistant chronic myeloid leukemia CML. These findings by a team of ARIAD scientists were used to guide...
- Research articles 2007-10-09
- ARIAD to Present AP23573, Novel mTOR Inhibitor, as One of Windhover's Top-Ten Cancer Projects at Oncology Conference
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that it will present a clinical and commercial update today on AP23573 - its novel mTOR inhibitor - at Windhover's Therapeutic Alliances Series: Oncology Conference at the Westin Peachtree Plaza in Atlanta, Georgia. Windhover has chosen ARIAD's lead oncology product candidate,...
- Research articles 2006-06-07
- ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Pierre F. Dodion, M.D., to the newly created position of senior vice president, oncology. In this role, Dr. Dodion will lead medical research, medical affairs, clinical operations, drug safety and pharmacovigilence and biostatistics and outcomes research at...
- Research articles 2007-06-13
- Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United States Adopted Names USAN Council and the World Health Organization WHO have approved the name "deforolimus" for AP23573, ARIAD's proprietary mTOR inhibitor. ARIAD and Merck & Co., Inc. have a global collaboration to jointly develop and commercialize...
- Research articles 2007-08-01
- ARIAD to Webcast Presentation at the 26th Annual JPMorgan Healthcare Conference
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 26th Annual JPMorgan Healthcare Conference, being held January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide a...
- Research articles 2008-01-02
- Court Ruling Raises Concerns About Ariad's Conduct and Patents
- Derek Lowe submits: Over the years on this blog, I’ve written quite a few times about Ariad Pharmaceuticals ARIA and their quest to assert some rather sweeping patent rights. For background, see here and search for "Ariad" - there's a lot to read, if you're in the mood. The...
- External links 2008-09-25
- ARIAD To Webcast Presentation at the Bear Stearns 20th Annual Healthcare Conference
- CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its presentation at the Bear Stearns 20th Annual Healthcare Conference at The Grand Hyatt in New York, New York on Monday, September 10, 2007 will be webcast live and can be accessed by visiting the investor relations section of...
- Research articles 2007-09-04
- ARIAD Announces Extension of the Expiration Date of Its Common Stock Purchase Warrants
- CAMBRIDGE, Mass.--BUSINESS WIRE--May 18, 1999-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the exercise deadline for its Common Stock Purchase Warrants has been extended from 5:00 p.m. New York City time on May 20, 1999 to 5:00 p.m. New York City time on December 30, 1999. The extension...
- Research articles 1999-05-18
- << Previous
- page 1 of 1
- Next >>
